McKinley Kate 4
4 · Rani Therapeutics Holdings, Inc. · Filed Dec 19, 2023
Insider Transaction Report
Form 4
McKinley Kate
Chief Business Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-12-16+250,000→ 250,000 totalExercise: $2.84Exp: 2033-05-21→ Class A Common Stock (250,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-16−250,000→ 0 totalExercise: $4.13Exp: 2033-05-21→ Class A Common Stock (250,000 underlying)
Footnotes (2)
- [F1]The shares subject to the option vest as follows: 25% of the shares subject to the option vest on May 22, 2024; and 1/48th of the shares subject to the option vest monthly over the remaining three years.
- [F2]The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options.